Neuroendocrine

New hope in treating advanced grade 3 Neuroendocrine Neoplasms – Garcia-Carbonero’s Lab

Garcia-Carbonero’s Lab shared a post on X:

“New hope in treating advanced grade 3 Neuroendocrine Neoplasms!

 The NICE-NEC trial (GETNE-T1913) shows Nivolumab and platinum-doublet chemo can extend survival for over a third of patients.

Median OS: 13.9 months; 37.6% are long-term survivors.”

Neuroendocrine

Source: Garcia-Carbonero’s Lab/X

Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913).

Authors: Maria Carmen Riesco-Martinez, Jaume Capdevila, Vicente Alonso, Paula Jimenez-Fonseca, Alex Teule, Enrique Grande, Isabel Sevilla, Marta Benavent, Teresa Alonso-Gordoa, Ana Custodio, Beatriz Anton-Pascual, Jorge Hernando, Eduardo Polo, Oscar Alfredo Castillo-Trujillo, Arantza Lamas-Paz, Ana Teijo, Yolanda Rodriguez-Gil, Beatriz Soldevilla and Rocio Garcia-Carbonero.

Neuroendocrine

Alex Teule Ana Custodio Ana Teijo Arantza Lamas-Paz Beatriz Anton-Pascual Beatriz Soldevilla cancer Eduardo Polo Enrique Grande Garcia-Carbonero's Lab Isabel Sevilla Jaume Capdevila Jorge Hernando Maria Carmen Riesco-Martinez Marta Benavent Neuroendocrine Neoplasms NICE-NEC trial nivolumab OncoDaily Oncology Oscar Alfredo Castillo-Trujillo Paula Jimenez-Fonseca Rocio Garcia-Carbonero Teresa Alonso-Gordoa Vicente Alonso Yolanda Rodriguez-Gil